AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_02_05_2025_05_53_40_418159.jpg)
Highlights
Enterome announces funding to progress clinical trials of its OncoMimics™ therapy targeting indolent non-Hodgkin lymphoma
Phase 1/2 SIDNEY study to be expanded and finalized with new backing
Collaboration with blood cancer research foundation deepens with fresh support
Paris-based Enterome SA, a clinical-stage biopharmaceutical company, continues advancing its cancer-focused immunotherapy initiatives through the development of its proprietary OncoMimics™ platform. The company operates outside the main UK indices, including FTSE 100, FTSE 350, and FTSE AIM UK 50 INDEX, yet remains a significant contributor to immuno-oncology innovation.
Funding Round Supports Clinical-Stage Advancement
Enterome announced the completion of a private financing round aimed at supporting the continued development of EO2463, its lead OncoMimics™ candidate. The therapy is currently undergoing evaluation in the SIDNEY Phase 1/2 clinical trial for the treatment of multiple forms of indolent non-Hodgkin lymphoma (iNHL). The financing will allow the company to conclude ongoing clinical evaluations and prepare for a future registrational trial, marking a major milestone in its therapeutic pipeline.
Focus on Follicular Lymphoma Treatment Innovations
A substantial portion of the newly acquired financing comes from The Institute for Follicular Lymphoma Innovation (IFLI), a foundation focused on improving outcomes for patients with follicular lymphoma. The support from IFLI enhances Enterome’s capacity to address one of the most common subtypes of iNHL, especially among patients within the “watch-and-wait” category, who typically receive limited or delayed treatment due to concerns surrounding the safety of existing therapies.
Therapeutic Approach Emphasizes Safety and Efficacy
EO2463 is designed as a first-in-class immunotherapy to stimulate the body’s immune response to mimic tumor-specific antigens. According to interim clinical results shared during a leading hematology conference, patients within the SIDNEY study have shown promising biological responses, particularly in the untreated iNHL subgroup. The immunotherapy has demonstrated clinical activity with minimal adverse effects, which is a critical factor in this patient population.
Industry Recognition and Expanded Collaboration
The financing round also included support from a mix of existing specialist backers, including biotechnology-focused venture capital firms and health foundations. Their continued engagement signals a broader commitment to immunotherapeutic development in hematologic malignancies. Enterome's collaborative network is playing a central role in supporting clinical validation, paving the way for broader adoption of immune-based strategies in cancer therapy.
Clinical Development Momentum Grows
EO2463 remains central to Enterome’s broader oncology strategy. The therapy is being studied both as a monotherapy and in combination with other agents. With the company’s current focus on patient populations underserved by conventional treatments, further momentum from the SIDNEY trial could shape new therapeutic pathways within the iNHL space.
The company’s approach reflects a growing trend in personalized medicine and immuno-oncology, utilizing the immune system’s specificity to tackle complex and often treatment-resistant malignancies. As development progresses, the data generated from EO2463’s clinical program is expected to inform subsequent clinical strategies and future regulatory engagement.
